| HOME >> BIOLOGY >> TECHNOLOGY |
Revenue $ - $ - $20 $10
Operating expenses:
Research and development 67,574 61,480 126,019 125,268
General and administrative 13,290 13,913 28,930 27,463
Total operating expenses 80,864 75,393 154,949 152,731
Loss from operations (80,864) (75,393) (154,929) (152,721)
Other income (expense) (60) 44 - 96
Interest expense on senior
convertible notes (124) (901) (461) (2,046)
Interest income 1,222 4,261 4,143 9,541
Loss before provision for
income taxes (79,826) (71,989) (151,427) (145,130)
Income taxes - - - -
Net loss $(79,826) $(71,989) $(151,247) $(145,130)
Net loss per share -
basic and diluted $ (0.79) $ (0.98) $ (1.49) $ (1.98)
Shares used to compute basic
and diluted net loss
per share 101,427 73,421 101,418 73,405
MannKind Corporation
Condensed Balance Sheet
(Unaudited)
(in thousands)
June 30, December 31,
Assets 2008 2007
Current assets:
Cash and cash equivalents $180,454 $368,285
State research and development tax credit
exchange receivable - current - 831
Prepaid expenses and other current assets 7,253 9,596
Total current assets 187,707 378,712
Propert
'/>"/>
| SOURCE MannKind Corporation Copyright©2008 PR Newswire. All rights reserved |